Specifically, participants in the higher Cum-eGDR quartiles (Q4 vs. Q1) exhibited significantly better baseline insulin sensitivity markers [higher eGDR (W1), lower TyG (W1) and TyG-BMI (W1); all P < 0.001], lower baseline frailty levels [Fi-score (W1); P < 0.001], and a significantly lower prevalence of baseline cardiovascular disease (heart disease or stroke; Baseline-CVD; P < 0.001). This evidence concerns the gene INS and cardiovascular disorder.